1Centro Nacional de Genética Medica- ANLIS- C.A.B.A - Argentina 2Hospital de Alta Complejidad en Red El Cruce – SAMIC, Provincia. de Buenos Aires, Argentina 31° Unidad académica de Histología, Embriología, Biología Celular y Genética, Facultad de Medicina UBA. 4Hospital de Alta Complejidad en Red El Cruce – SAMIC, Provincia de Buenos Aires, Argentina 5Hospital de Alta Complejidad en Red El Cruce – SAMIC, Pcia. de Buenos Aires, Argentina 6Novagen, C.A.B.A. Argentina 7Centro Nacional de Genética Medica- ANLIS-C.A.B.A- Argentina 8Departamento de Fisiología, Biología Molecular y Celular, Instituto de Biociencias, Biotecnología y Biología Traslacional (iB3), Facultad de Ciencias Exactas y Naturales- UBA, C.A.B.A, Argentina 9Centro de Investigaciones Endocrinológicas ¨Dr. Cesar Bregada 10Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas 11Hospital Interzonal General de Agudos Luisa Cravenna de Gandulfo, Provincia de Buenos Aires, Argentina 12Hospital Sor Maria Ludovica, La Plata, Provincia. de Buenos Aires Argentina 13Hospital Materno Infantil Ramón Sardá, C.A.B.A, Argentina 14Centro Nacional de Genética Medica- ANLIS- C.A.B.A- Argentina
Introduction: Congenital anomalies (CA) affects 3-5 % of newborns, representing the second leading cause of infant mortality in Argentina. Newborns presenting multiple congenital anomalies (MCA) have a prevalence of 2,26/1000 births while congenital heart diseases (CHD) are the most frequent CA, with a prevalence of 4,06/1000 births. The goal of this work was to identify the genetic causes in patients with MCA and isolated CHD (iCHD) from Argentina.
Material and Methods: We recruited 368 patients (174 MCA and 194 iCHD) born between June 2015 and August 2019 from 13 public hospitals participating in the National Network of Congenital Anomalies of Argentina (RENAC). DNA from peripheral blood was obtained from all patients while karyotyping was performed for those patients presenting with MCA. Samples from patients presenting with conotruncal CHD (cCHD) or DiGeorge phenotype (n=137) were analyzed by MLPA. Ninety-two MCA samples were selected for array-CGH analysis and 18 for targeted or exome next generation sequencing (NGS).
Results: A total of 276 patients were studied by at least one technique. Cytogenetic abnormalities were present in 16 MCA patients, while 16 had clinically relevant imbalances detected by array-CGH. Among cCHD patients, 26 presented 22q11 deletions or duplications and one a TBX1 gene deletion. After NGS analysis, 12 patients presented clinically relevant nucleotide variants, 5 of them novels in KAT6B, SHH, MYH11, MYH7 and EP300 genes.
Conclusions: Using this algorithm that combines a technical and clinical strategy, 28% of the patients analyzed were diagnosed.
Delea, M.; Massara, L.S.; Espeche, L.D.; Bidondo, M.P.; Oliveri, J.; Brun, P.; Fabbro, M.; Galain, M.; Fernandez, C.S.; Taboas, M.I.; Bruque, C.D.; Kolomenski, E.; Izquierdo, A.; Berenstein, A.; Barbero, P.; Cosentino, V.; Martinoli, C.; Vilas, M.; Rittler, M.; Mendez, R.; Furforo, L.; Liascovich, R.; Groisman, B.; Rozental, S.; Dain, L. Genetic analysis algorithm for the study of patients with Multiple Congenital Anomalies and isolated Congenital Heart Disease, in Proceedings of the 1st International Electronic Conference on Genes: Theoretical and Applied Genomics, 2–30 November 2020, MDPI: Basel, Switzerland, doi:10.3390/IECGE-07151
